Henry Schein, Inc. (NASDAQ:HSIC) Given Consensus Recommendation of “Hold” by Analysts

Shares of Henry Schein, Inc. (NASDAQ:HSIC) have received an average rating of “Hold” from the fifteen ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $92.2667.

HSIC has been the subject of a number of recent analyst reports. Robert W. Baird set a $97.00 price target on shares of Henry Schein in a research report on Wednesday, May 6th. Mizuho cut their price target on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Barclays reiterated an “overweight” rating and set a $100.00 price objective (up from $86.00) on shares of Henry Schein in a research note on Thursday, August 6th. Weiss Ratings reissued a “hold (c+)” rating on shares of Henry Schein in a report on Friday, July 31st. Finally, UBS Group set a $94.00 target price on shares of Henry Schein and gave the stock a “neutral” rating in a research report on Wednesday, August 5th.

Institutional Trading of Henry Schein

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Invesco Ltd. raised its stake in Henry Schein by 4.1% during the third quarter. Invesco Ltd. now owns 4,731,698 shares of the company’s stock valued at $314,043,000 after buying an additional 184,763 shares in the last quarter. Southpoint Capital Advisors LP grew its position in shares of Henry Schein by 28.0% in the 1st quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company’s stock worth $235,840,000 after acquiring an additional 700,000 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Henry Schein by 2.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,873,004 shares of the company’s stock valued at $211,734,000 after acquiring an additional 56,687 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in shares of Henry Schein by 11.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 2,523,014 shares of the company’s stock valued at $167,453,000 after acquiring an additional 256,156 shares during the last quarter. Finally, Bank of Montreal Can raised its position in shares of Henry Schein by 3,655.7% during the 4th quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock valued at $162,102,000 after acquiring an additional 2,087,666 shares in the last quarter. 96.62% of the stock is owned by institutional investors.

Henry Schein Trading Down 0.4%

NASDAQ:HSIC opened at $89.77 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.73 and a current ratio of 1.32. Henry Schein has a one year low of $61.94 and a one year high of $92.18. The business’s 50-day simple moving average is $84.81 and its 200 day simple moving average is $79.06. The stock has a market cap of $10.00 billion, a price-to-earnings ratio of 26.17, a price-to-earnings-growth ratio of 1.71 and a beta of 0.80.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, beating analysts’ consensus estimates of $1.24 by $0.03. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%.The firm had revenue of $3.46 billion during the quarter, compared to analyst estimates of $3.37 billion. During the same quarter last year, the firm earned $1.10 EPS. Henry Schein’s quarterly revenue was up 6.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. As a group, sell-side analysts predict that Henry Schein will post 5.35 earnings per share for the current fiscal year.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.